Clyde BioSciences Limited

www.clydebio.com/ www.linkedin.com/company/clyde-biosciences-ltd/

Clyde Biosciences specializes in measuring and interpreting drug effects on cardiac cell function at clinically relevant doses. The company’s proprietary technology combines a range of human stem cell and other relevant in vitro phenotypes with a sensitive, data-rich measurement system and expert interpretation. The platform is demonstrably capable of screening-level throughput providing a more complete assessment of cardiovascular efficacy and safety with in vivo and clinical predictability.

Clyde’s CellOPTIQ® platform generates human relevant cardiomyocyte functional data to enable faster, safer, and more accurate development of new medicines, reducing cost and increasing success.

Clyde is the only validated CRO for the CiPA Assay.

Richard Henderson

Chief Executive Officer

+44 771 787 8188 rdh@clydebio.com

Mark Bryant

Chief Business Officer

+44 780 181 6212 mb@clydebio.com